Incyte Corporation (INCY)

業務介紹

Incyte Corporation是一家生物製藥公司，專注於在美國和國際市場上發現、開發和商業化專利治療藥物。該公司提供JAKAFI，一種用於治療骨髓纖維化和多紅細胞增多症的藥物；PEMAZYRE，一種纖維母細胞生長因子受體激酶抑制劑，可作為各種液體和實體腫瘤類型的致癌驅動因子；以及ICLUSIG，一種激酶抑制劑，用於治療慢性骨髓性白血病和費城染色體陽性急性淋巴細胞白血病。其臨床階段產品包括魯索利替尼，一種類固醇難治性慢性移植物抗宿主病（GVHD）的藥物；伊他西替尼，正在進行II/III期臨床試驗，用於治療初發性慢性GVHD；以及佩米加替尼，用於治療膀胱癌、膽管癌、骨髓增生綜合症和腫瘤不可知性。此外，該公司還致力於開發帕沙克利西，該藥正在進行II期臨床試驗，用於治療濾泡性淋巴瘤、邊緣區淋巴瘤和曼特爾細胞淋巴瘤。此外，該公司還開發了Retifanlimab，該藥正在進行II期臨床試驗，用於治療MSI高度子宮內膜癌、梅克爾細胞癌和肛門癌，以及用於非小細胞肺癌患者的II期臨床試驗。該公司與諾華國際製藥有限公司、愛麗莉莉公司、Agenus Inc.、Calithera Biosciences, Inc.、MacroGenics, Inc.、Merus N.V.、Syros Pharmaceuticals, Inc.、Innovent Biologics, Inc.、Zai Lab Limited、Cellenkos, Inc.和Nimble Therapeutics等公司簽訂了合作協議，並與MorphoSys AG和Xencor, Inc.進行臨床合作，研究tafasitamab、plamotamab和lenalidomide在復發或難治性弥漫大B细胞淋巴瘤和復發或難治性濾泡性淋巴瘤患者中的組合應用。該公司成立於1991年，總部位於特拉華州威明頓市。

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

公司網址

https://www.incyte.com